Article thumbnail

A Cell-Based Assay for RNA Synthesis by the HCV Polymerase Reveals New Insights on Mechanism of Polymerase Inhibitors and Modulation by NS5A

By C. T. Ranjith-Kumar, Yahong Wen, Nielson Baxter, Kanchan Bhardwaj and C. Cheng Kao

Abstract

RNA synthesis by the genotype 1b hepatitis C virus (HCV) polymerase (NS5B) transiently expressed in Human embryonic kidney 293T cells or liver hepatocytes was found to robustly stimulate RIG-I-dependent luciferase production from the interferon β promoter in the absence of exogenously provided ligand. This cell-based assay, henceforth named the 5BR assay, could be used to examine HCV polymerase activity in the absence of other HCV proteins. Mutations that decreased de novo initiated RNA synthesis in biochemical assays decreased activation of RIG-I signaling. In addition, NS5B that lacks the C-terminal transmembrane helix but remains competent for RNA synthesis could activate RIG-I signaling. The addition of cyclosporine A to the cells reduced luciferase levels without affecting agonist-induced RIG-I signaling. Furthermore, non-nucleoside inhibitor benzothiadiazines (BTDs) that bind within the template channel of the 1b NS5B were found to inhibit the readout from the 5BR assay. Mutation M414T in NS5B that rendered the HCV replicon resistant to BTD was also resistant to BTDs in the 5BR assay. Co-expression of the HCV NS5A protein along with NS5B and RIG-I was found to inhibit the readout from the 5BR assay. The inhibition by NS5A was decreased with the removal of the transmembrane helix in NS5B. Lastly, NS5B from all six major HCV genotypes showed robust activation of RIG-I in the 5BR assay. In summary, the 5BR assay could be used to validate inhibitors of the HCV polymerase as well as to elucidate requirements for HCV-dependent RNA synthesis

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3142182
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2004). A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication.
  2. (2010). A Investigational drugs for hepatitis C.
  3. (2008). A locking mechanism regulates RNA synthesis and host protein interaction by the hepatitis C virus polymerase.
  4. (1999). A recombinant hepatitis C virus RNA-dependent RNA polymerase capable of copying the full-length viral RNA.
  5. (2009). Agonist and antagonist recognition by RIG-I, a cytoplasmic innate immunity receptor.
  6. (2010). An update on small molecule inhibitors of the HCV NS5B polymerase: effects on RNA synthesis in vitro and in cultured cells, and potential resistance in viral quasispecies. Virus Adaptation and Treatment
  7. (2007). Biochemical and functional analyses of the human Toll-like receptor 3 ectodomain.
  8. (2005). Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus.
  9. (2004). Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides.
  10. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
  11. (2005). Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling.
  12. (1999). Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site.
  13. (1999). Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus.
  14. (2005). Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase.
  15. (2004). De novo initiation pocket mutations have multiple effects on hepatitis C virus RNAdependent RNA polymerase activities.
  16. (1999). Differential detergent fractionation of eukaryotic cells. Analysis by two-dimensional gel electrophoresis.
  17. (2005). Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNAdependent RNA polymerase.
  18. (2004). Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon.
  19. (2000). Efficient initiation of HCV RNA replication in cell culture.
  20. (2005). Efficient rescue of hepatitis C virus RNA replication by trans-complementation with nonstructural protein 5A.
  21. (2010). Green tea catechin, epigallocatechin gallate, suppresses signaling by the dsRNA innate immune receptor RIG-I.
  22. (2002). Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity.
  23. (2008). High relapse rate seen at week 72 for patients treated with R1626 combination therapy.
  24. (2002). Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.
  25. (2005). Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3.
  26. (2005). Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Tolllike receptor 3 adaptor protein TRIF.
  27. (2000). Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy.
  28. (2002). Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers.
  29. (2007). Interferon-beta is activated by hepatitis C virus NS5B and inhibited by NS4A, NS4B, and NS5A.
  30. (2006). Intracellular pattern recognition receptors in the host response.
  31. (2005). IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction.
  32. (2008). Lengthdependent recognition of double-stranded ribonucleic acids by retinoic acidinducible gene-I and melanoma differentiation-associated gene 5.
  33. (2002). Mechanism of de novo initiation by the hepatitis C virus RNA-dependent RNA polymerase: role of divalent metals.
  34. (2003). Multiple interactions within the hepatitis C virus RNA polymerase repress primerdependent RNA synthesis.
  35. (2007). New drugs for hepatitis C virus.
  36. (2011). New HCV therapies on the horizon.
  37. (2010). New NS5B polymerase inhibitors for hepatitis C.
  38. (2006). NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon.
  39. (2010). NS5B RNA dependent RNA polymerase inhibitors: the promising approach to treat hepatitis C virus infections.
  40. (2000). Peginterferon alfa-2a in patients with chronic hepatitis C.
  41. (2005). Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase,
  42. (1999). Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.
  43. (2007). RIG-I family RNA helicases: cytoplasmic sensor for antiviral innate immunity.
  44. (2010). Secretion of the human Toll-like receptor 3 ectodomain is affected by single nucleotide polymorphisms and regulated by Unc93b1.
  45. (2007). Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B.
  46. (2002). Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides.
  47. (2009). Structural and functional analysis of hepatitis C virus strain JFH1 polymerase.
  48. (2008). Structural basis of toll-like receptor 3 signaling with double-stranded RNA.
  49. (2009). Substituted benzothiadizine inhibitors of Hepatitis C virus polymerase.
  50. (1979). The broad spectrum antiviral agent ribavirin inhibits capping of mRNA.
  51. (2009). The Hepatitis C Virus NS5A Stimulates NS5B During In Vitro RNA Synthesis in a Template Specific Manner.
  52. (2004). The RNA helicase RIG-I has an essential function in double-stranded RNAinduced innate antiviral responses.
  53. (2010). The structural basis of 59 triphosphate double-stranded RNA recognition by RIG-I C-terminal domain.
  54. (2000). The structure of inosine 59-monophosphate dehydrogenase and the design of novel inhibitors.
  55. (2008). The TLR3 signaling complex forms by cooperative receptor dimerization.
  56. (2009). Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells.
  57. (2006). Trans-complementation of HCV replication by non-structural protein 5A.
  58. (2004). Understanding hepatitis C.
  59. (2005). VISA is an adapter protein required for virus-triggered IFN-beta signaling.